Sales & Marketing Sponsored 5 forces reshaping pharma commercialisation in 2026 As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment
Patients Sponsored From insight to impact: Why the patient voice will redefine ... Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?
Digital Sponsored The imperative for patient centricity in clinical research i... Read uMotif's Observations & Predictions on the imperative for patient centricity and stronger patient-site relationships in clinical research.
R&D Sponsored Obesity, complexity, and the lab: What 2025 taught us, and w... The complexity of working with the patient population in obesity continues to challenge traditional trial design. hVIVO looks to the year ahead.
Digital Sponsored Clinical trials at the core: Decentralised, AI targeted, ESG... For Inventus' Steve Sanghera and Jim Michel 2025 was a year of progress in clinical trial enablement.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
News Pulmonary fibrosis drug developer Avalyn files IPO Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.